{"id":"NCT00829179","sponsor":"Duke University","briefTitle":"Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma","officialTitle":"Role of RhuMab-E25 in Reducing Exhaled NO in Allergic Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-10","primaryCompletion":"2004-07","completion":"2004-07","firstPosted":"2009-01-26","resultsPosted":"2009-10-21","lastUpdate":"2016-02-08"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Allergic Asthma"],"interventions":[{"type":"DRUG","name":"RhuMab-E25","otherNames":["Omalizumab"]}],"arms":[],"summary":"A single center pilot study to determine the protective effects of RhuMAB-E25 on airway physiology and biology in allergic asthmatics that undergo bronchoprovocation with methacholine.\n\nThe primary study objective determines the protective impact of RhuMAB-E25 on airway inflammation as reflected in exhaled nitric oxide (NO) levels in allergic asthmatics.\n\nThe secondary objective determines the protective effect of rhuMAB E25 against airway bronchoconstriction as reflected in the Provocative Concentration of methacholine to cause a 20% fall in FEV1(PC20) with methacholine challenge testing.","primaryOutcome":{"measure":"Change in Exhaled Nitric Oxide From Baseline to Week 12","timeFrame":"13 weeks","effectByArm":[{"arm":"RhuMab-E25","deltaMin":-11,"sd":13.3}],"pValues":[{"comp":"OG000","p":"0.005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["viral syndrome","headache","cough"]}}